弥漫性胶质瘤生物标志物的发现及研究进展

发布时间：2018-05-07 01:24

  本文选题：胶质瘤 + 生物标志物　； 参考：《中国临床药理学与治疗学》2016年01期

【摘要】：弥漫性胶质瘤是成人中最常见的原发性中枢神经系统肿瘤,分为星形细胞瘤、少突胶质细胞瘤和少突星形细胞瘤,病理级别为Ⅱ~Ⅳ级,其中Ⅳ级的胶质母细胞瘤是最常见的高级别胶质瘤。传统上弥漫性胶质瘤的诊断主要是基于其组织病理学特征,但是仍有很多生物学特点无法很好地解释。而以异柠檬酸脱氢酶(IDH)为代表的生物标志物已被证明对脑胶质瘤分子特征的分类和患者预后情况都有不可忽视的作用。IDH在成人Ⅱ级和Ⅲ级弥漫性胶质瘤及继发性胶质母细胞瘤中突变频率较高。IDH突变的浸润性星形细胞瘤和继发性胶质母细胞瘤具有TP53和ATRX突变的特点。少突胶质细胞瘤也伴随IDH突变并以1p/19q联合性缺失和CIC、FUBP1、Notch1、TERT启动子突变为特征。胶质瘤的生物标志物有望成为临床诊断的新标准。
[Abstract]:Diffuse gliomas are the most common primary central nervous system tumors in adults. They are divided into astrocytoma, oligodendrocytoma and oligodendrocytoma. Grade IV glioblastoma is the most common high grade glioma. Traditionally, the diagnosis of diffuse glioma is mainly based on its histopathological features, but there are still many biological characteristics that can not be explained well. However, the biomarker represented by isocitrate dehydrogenase (IDH) has been proved to play an important role in the classification of glioma molecular characteristics and the prognosis of the patients. IDH plays an important role in diffuse gliomas and secondary gliomas of grade 鈪，

本文编号：1854780